Alexion’s blockbuster Soliris (eculizumab) could face biosimilar competition in Brazil after a court upheld a decision stipulating that the so-called mailbox patent relating to the product expired in 2015. According to the prosecutors in the case, other drugs could be similarly affected.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?